Related references
Note: Only part of the references are listed.Protective efficacy of several vaccines against highly pathogenic H5N1 avian influenza virus under experimental conditions
Jutta Veits et al.
VACCINE (2008)
Vaccination of Macaques with adjuvanted formalin-inactivated influenza a virus (H5N1) vaccines: Protection against H5N1 challenge without disease enhancement
Caroline Ruat et al.
JOURNAL OF VIROLOGY (2008)
Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine:: a randomised controlled trial
Isabel Leroux-Roels et al.
LANCET (2007)
Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses
Otfried Kistner et al.
VACCINE (2007)
Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1
Joost H. C. M. Kreijtz et al.
JOURNAL OF INFECTIOUS DISEASES (2007)
Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model
Ai Ninomiya et al.
VACCINE (2007)
Harvesting and concentration of human influenza A virus produced in serum-free mammalian cell culture for the production of vaccines
Bernd Kalbfuss et al.
BIOTECHNOLOGY AND BIOENGINEERING (2007)
Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial
Jiangtao Lin et al.
LANCET (2006)
Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: A phase I/II trial
Richard Harrop et al.
CLINICAL CANCER RESEARCH (2006)
Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine:: phase I randomised trial
Jean-Louis Bresson et al.
LANCET (2006)
H5N1 virus attachment to lower respiratory tract
D van Riel et al.
SCIENCE (2006)
Expression of hemagglutinin protein from the avian influenza virus H5N1 in a baculovirus/insect cell system significantly enhanced by suspension culture
N Nwe et al.
BMC MICROBIOLOGY (2006)
Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice
MA Hoelscher et al.
LANCET (2006)
Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization
WT Gao et al.
JOURNAL OF VIROLOGY (2006)
Current concepts - Avian influenza A (H5N1) infection in humans
H Beigel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Generation of influenza vaccine viruses on Vero cells by reverse genetics: an H5N1 candidate vaccine strain produced under a quality system
C Nicolson et al.
VACCINE (2005)
Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?
I Drexler et al.
CURRENT OPINION IN BIOTECHNOLOGY (2004)
Are we ready for pandemic influenza?
RJ Webby et al.
SCIENCE (2003)
Pathology of human influenza A (H5N1) virus infection in cynomolgus macaques (Macaca fascicularis)
T Kuiken et al.
VETERINARY PATHOLOGY (2003)
Pathogenesis of influenza A (H5N1) virus infection in a primate model
GF Rimmelzwaan et al.
JOURNAL OF VIROLOGY (2001)
Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza
KG Nicholson et al.
LANCET (2001)
Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques
KJ Stittelaar et al.
VACCINE (2001)
Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans
JJ Treanor et al.
VACCINE (2001)
Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector
JC Ramírez et al.
JOURNAL OF VIROLOGY (2000)